Positive Earnings Growth Hasn't Been Enough to Get Baolingbao BiologyLtd (SZSE:002286) Shareholders a Favorable Return Over the Last Three Years
Positive Earnings Growth Hasn't Been Enough to Get Baolingbao BiologyLtd (SZSE:002286) Shareholders a Favorable Return Over the Last Three Years
This week we saw the Baolingbao Biology Co.,Ltd. (SZSE:002286) share price climb by 19%. But that cannot eclipse the less-than-impressive returns over the last three years. Truth be told the share price declined 36% in three years and that return, Dear Reader, falls short of what you could have got from passive investing with an index fund.
上周，保龄宝股份有限公司（SZSE：002286）的股票价格上涨了19％，但不能掩盖过去三年收益不佳的事实。 事实上，股价在三年内下跌了36％，亲爱的读者，这一回报不如您可以从指数基金的被动投资中获得的回报。
While the last three years has been tough for Baolingbao BiologyLtd shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.
虽然过去三年对保龄宝股份有限公司的股东来说非常艰难，但上周显示了一些希望的迹象。 因此，让我们查看更长期的基本面，看看它们是否是负回报的推动因素。
To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
引用巴菲特的话，“船只会在世界各地航行，但扁平地球协会将空前盛行。市场上的价格和价值将继续存在巨大差异… ”检查市场情绪如何随时间变化的一种方法是查看公司的股价与每股收益（EPS）之间的互动。
During the unfortunate three years of share price decline, Baolingbao BiologyLtd actually saw its earnings per share (EPS) improve by 11% per year. This is quite a puzzle, and suggests there might be something temporarily buoying the share price. Or else the company was over-hyped in the past, and so its growth has disappointed.
在不幸的三年股价下跌期间，保龄宝股份有限公司的每股收益（EPS）实际上每年提高了11％。 这是一个相当棘手的问题，并表明股价可能有一些暂时的支撑。 或者公司过去被过度炒作，因此其增长令人失望。
Since the change in EPS doesn't seem to correlate with the change in share price, it's worth taking a look at other metrics.
由于EPS的变化似乎与股价的变化不相关，因此值得查看其他指标。
The modest 1.3% dividend yield is unlikely to be guiding the market view of the stock. The company has kept revenue pretty healthy over the last three years, so we doubt that explains the falling share price. There doesn't seem to be any clear correlation between the fundamental business metrics and the share price. That could mean that the stock was previously overrated, or it could spell opportunity now.
1.3％的小额股息收益率不可能指导股市对该股票的看法。过去三年，公司的营业收入保持得相当稳健，因此我们怀疑这解释了股价下跌的原因。 基本业务指标与股价之间似乎没有明显的相关性。 这可能意味着该股票先前被高估了，或者现在可能有机会。
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
下面的图表显示了收益和营收随时间的变化情况（通过单击图像揭示确切的值）。
Take a more thorough look at Baolingbao BiologyLtd's financial health with this free report on its balance sheet.
使用有关其资产负债表的免费报告更全面地了解保龄宝股份有限公司的财务状况。
A Different Perspective
不同的观点
While the broader market lost about 16% in the twelve months, Baolingbao BiologyLtd shareholders did even worse, losing 30% (even including dividends). However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Longer term investors wouldn't be so upset, since they would have made 2%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Baolingbao BiologyLtd better, we need to consider many other factors. Even so, be aware that Baolingbao BiologyLtd is showing 3 warning signs in our investment analysis , you should know about...
虽然总体市场在十二个月中损失了约16％，但保龄宝股份有限公司的股东表现得更糟糕，包括股息在内，损失了30％。 然而，股价可能仅仅受到整体市场恐慌的影响。 如果基本数据继续表明长期可持续增长，目前的抛售可能是值得考虑的机会。 长期的投资者不会那么不安，因为他们每年可以获得2％的回报，在五年内实现。 要更好地了解保龄宝股份有限公司，跟踪股价长期表现总是很有趣的。 但是，需要考虑许多其他因素才能更好地理解。 无论如何，请注意，保龄宝股份有限公司的投资分析显示出3个警告信号，您应该知道......
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
如果您愿意查看另一家公司-具有潜在更优质财务状况的公司-则不要错过这个免费的公司列表，这些公司已经证明他们可以增长收益。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意，本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈？关于内容有所顾虑？直接和我们联系。或者，发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论，只使用公正的方法论，我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议，也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意，我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈？关于内容有所顾虑？直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。